Prometheus provides clinical laboratory testing services and markets pharmaceutical products. In providing testing services, Prometheus receives, creates and discloses personal health information. In fulfilling regulatory requirements related to the pharmaceutical products, Prometheus may receive and disclose personal health information. This information is private and confidential. There are policies and procedures in place to protect the information against unlawful use and disclosure. This Notice describes information we collect, how we use that information, and when and to whom we may disclose it.
Prometheus is required by the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and other laws to maintain the privacy of protected health information, to provide notice of its legal duties and privacy practices and notify affected individuals in the event of a breach of their unsecured protected health information. Protected health information or "PHI" (also called "personal health information"), is current, past or future information created or received by Prometheus from physicians, patients, health plans or other sources. It is personal or medical information that relates to the physical condition of a patient, the provision of health care to that person, or payment for the provision of health care to that person. The term PHI does not generally include publicly available information, or information available or reported in a summarized or grouped manner.
This Notice describes how we may use or disclose your protected health information to carry out treatment, payment or health care operations and for other purposes that are permitted or required by HIPAA. This Notice also describes your rights of access to and control of your PHI. When we use or disclose PHI, we are required to abide by the terms of this Notice (or other notice in effect at the time of the use or disclosure).
Prometheus collects that information that is minimally necessary to provide testing services and to obtain payment for these services. This may include your name, address, telephone number, social security number, date of birth, medical history, diagnosis, treatment, provider identification and treatment information, financial responsibility and payment information.
Prometheus creates, through its testing services, information to be used by a physician in the diagnosis of disease or condition or in the treatment of a disease or condition.
Access to PHI is restricted to only those employees of Prometheus who need it in order to provide services to clients and patients. We maintain physical, technical and procedural safeguards to protect PHI against unauthorized use and disclosure. We have a Privacy Officer who is responsible for developing, educating Prometheus personnel about, and overseeing the implementation and enforcement of policies and procedures designed to safeguard PHI against inappropriate use and disclosure consistent with the applicable law.
In the course of providing laboratory services, Prometheus uses PHI internally and discloses it to health care providers (doctors requesting services, laboratory personnel involved in ordering services and other caregivers), insurers, third party administrators, plan sponsors and other payors (employers, health care provider organizations and others who may be responsible for paying for or administering your health benefits); vendors, consultants, government authorities; and their respective agents. They are required by law to keep PHI confidential. Some examples of what we do with the information we collect and the reasons it might be disclosed to third parties are described below.
Treatment, Payment and Healthcare Operations. We may use or disclose PHI with or without your authorization as follows:
Other Activities Permitted or Required by Law:
We may use or disclose PHI for other important activities permitted or required by law, with or without your authorization. These activities include the following:
We may not make the following uses or disclosures without your authorization:
Except as otherwise described in this Notice, we will not use or disclose your PHI without your written authorization. You have the right to revoke your authorization in writing at any time except to the extent that Prometheus has taken action in reliance on your authorization.
It is possible to request that we disclose PHI to people in ways not described above. To authorize us to disclose your personal health information to a person or organization or for reasons other than those described in the section above, see the contact information at the bottom of this page. If you make a special authorization and later change your mind about this, you may send a letter to us to let us know that you would like to revoke the special authorization. In any communication with us, please provide your name, address, patient identification number or Social Security number, and a telephone number where we can reach you in case we need to contact you about your request.
This Notice is published on the Prometheus web site at www.prometheuslabs.com\PrivacyNotice and is made available in printed form upon request.
We may change the terms of this notice at any time. If we change this notice, we may make the new notice terms effective for all PHI that we maintain, including any information created or received prior to issuing the new notice. If we change this notice, we will post the new notice on our Internet site at www.prometheuslabs.com.
As a convenience, Prometheus may make available email addresses by which you can communicate with us regarding billing issues. Please be advised that email is not a secure means of communication, therefore Prometheus cannot guarantee the security of any information that you send to us prior to our receipt of it. This fact may also restrict our use of email in communicating any response to you - we will make every attempt to use alternate means of communicating anything that may be considered sensitive information.
Prometheus takes privacy and security very seriously. With regard to "Do Not Track Signals" (DNT), Prometheus currently does not respond to DNT signals in browsers because we do not track individual users across the web.
Prometheus does not authorize the collection of PHI or other personally identifiable information from our website users for third party use through advertising technologies without separate user consent.
If you would like a paper copy of this notice, have questions about it, or believe its terms or any Prometheus privacy or confidentiality policy has been violated with respect to information about you, please let us know immediately by contacting us toll-free at 1-888-423-5227 and request the Compliance/Privacy Office. Please include your name, address, and a telephone number where we can contact you, and a brief description of the complaint. If you prefer, you may lodge an anonymous complaint.
Prometheus Laboratories Inc.
9410 Carroll Park Drive
San Diego, CA 92121
Or call our Ethics Hotline at 1-888-PRO-RXDX (776-7939)
You also may contact the Secretary of the Department of Health and Human Services at:
The U.S. Department of Health and Human Services
200 Independence Avenue, S.W.
Washington, D.C. 20201
Toll Free: 1-877-696-6775
Please provide as much information as possible so that the complaint can be properly investigated. Prometheus will not retaliate against a person who files a complaint with us or with the Secretary of the Department of Health and Human Services.
INDICATION: LOTRONEX/alosetron hydrochloride is indicated only for women with severe diarrhea-predominant irritable bowel syndrome who have: chronic irritable bowel syndrome symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. Diarrhea-predominant irritable bowel syndrome is severe if it includes diarrhea and one or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to irritable bowel syndrome. Because of infrequent but serious gastrointestinal adverse events associated with LOTRONEX/alosetron hydrochloride, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable. Clinical studies have not been performed to adequately confirm the benefits of LOTRONEX/alosetron hydrochloride in men.
PEDIATRIC USE: Safety and effectiveness have not been established in pediatric patients.
IMPORTANT SAFETY INFORMATION: Infrequent but serious gastrointestinal adverse events have been reported with the use of LOTRONEX. These events, including ischemic colitis and serious complications of constipation, have resulted in hospitalization, and rarely, blood transfusion, surgery, and death. Some patients have experienced serious complications of constipation or ischemic colitis without warning. In IBS clinical trials, approximately 10% of patients on LOTRONEX withdrew prematurely because of constipation. The incidence of serious complications of constipation was approximately 0.1% (1 per 1,000 patients) in women receiving either LOTRONEX or placebo. In IBS clinical trials, the cumulative incidence of ischemic colitis in women receiving LOTRONEX was 0.2% (2 per 1,000 patients, 95% confidence interval 1 to 3) through 3 months and was 0.3% (3 per 1,000 patients, 95% confidence interval 1 to 4) through 6 months. Ischemic colitis was not reported in women receiving placebo. The patient experience in controlled clinical trials is insufficient to estimate the incidence of ischemic colitis in patients taking LOTRONEX for longer than 6 months.
LOTRONEX should be discontinued immediately in patients who develop constipation or symptoms of ischemic colitis such as rectal bleeding, bloody diarrhea or new or worsening abdominal pain. Patients should immediately report constipation or symptoms of ischemic colitis to their physician. LOTRONEX should not be resumed in patients who develop ischemic colitis. Patients who have constipation should immediately contact their physician if the constipation does not resolve after LOTRONEX is discontinued. Patients with resolved constipation should resume LOTRONEX only on the advice of their treating physician.
LOTRONEX should not be initiated in IBS patients who are constipated. LOTRONEX is contraindicated in patients with a history of chronic or severe constipation or a history of sequelae from constipation; with a history of intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions; with a history of ischemic colitis, impaired intestinal circulation, thrombophlebitis, or hypercoagulable state; with current or a history of Crohn's disease or ulcerative colitis; with severe hepatic impairment; with active diverticulitis or a history of diverticulitis; in patients who are unable to understand or comply with the Patient-Physician Agreement; and/or in patients with known hypersensitivity to any component of the product. Concomitant administration of alosetron with fluvoxamine is contraindicated.
DOSING: To lower the risk of constipation, LOTRONEX should be started at a dosage of 0.5 mg twice a day. Patients well controlled on 0.5 mg twice a day may be maintained on this regimen. If, after 4 weeks, the 0.5-mg twice-daily dosage is well tolerated but does not adequately control IBS symptoms, then the dosage can be increased to up to 1 mg twice a day, the dose used in controlled clinical trials. LOTRONEX should be discontinued in patients who have not had adequate control of IBS symptoms after 4 weeks of treatment with 1 mg twice per day. LOTRONEX should be used with caution in debilitated patients, elderly patients, patients with mild or moderate hepatic impairment, and patients taking medications that decrease gastrointestinal motility. LOTRONEX should not be used in patients with severe hepatic impairment.